| Biotech CROs Take Center Stage in Recent Deals The Burrill Report submits: By Marie DaghlianGlobal contract research services firm Charles River Laboratories (CRL) is expanding its presence in China with the acquisition of WuXi PharmaTech (WX), a major drug research and development outsourcing company with expertise in discovery chemistry and operations in both China and the United States. The $1.6 billion cash and stock deal will expand the global reach and growth opportunities for both companies. Complete Story » seekingalpha.com |
Intellipharmaceutics CEO Molded by Biovail Bio Tuesday submits: Fifteen years ago, Dr. Isa Odidi performed magic as CSO of Biovail (NYSE:BVF), developing several blockbuster generics, including hard-to-manufacture copies of Bayer’s (BAYRY.PK) Adalat CC, Pfizer’s (PFE) Procardia XL and Novartis’ (NVS) Voltaren XR. “We have the same style here at Intellipharmaceutics (NASDAQ:IPCI) as we had at Biovail,” Dr. Odidi says in an exclusive interview with BioTuesday.ca. “It’s the library system approach. If you want a book at the library, you take it off the shelf. Likewise, we have a lot of compounds at various stages of development and as we file one, we bring another one forward.”Complete Story » seekingalpha.com |
Abbott Posts Flat Earnings Abbott Labs said its earnings were flat as acquisition costs offset double-digit sales growth. online.wsj.com |
Good Signs Abound for Forest's New Antibiotic EP Vantage submits:Forest Laboratories’ (FRX) ceftaroline received a surprisingly unanimous backing Tuesday from an FDA advisory committee, boding well for final approval from the FDA. The relatively smooth passage also suggests that concerns that the antibiotic might be tripped up by the ongoing debate around the evaluation of such products in the US were overstated. As such, after a pretty torrid time for antibiotic approvals in the US, other companies approaching the FDA with late stage antibiotics could well be taking comfort from ceftaroline’s progress so far.Complete Story » seekingalpha.com |
BioClinica Responds to Shareholder Letter [Business Wire] - BioClinicaâ„¢, Inc. , a global provider of clinical trial management services, has issued the following statement: us.rd.yahoo.com |